In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

Abstract AFN-1252 is a novel inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0·015 μg/ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. We now report high binding (∼95%) to serum proteins of mouse, rat, dog and humans, associated with an eight-fold increase in minimal inhibitory concentration (MIC) and which may be responsible for the long elimination half-lives on pharmacokinetic studies. Unlike daptomycin, AFN-1252 activity is not reduced in the presence of lung surfactant. AFN-1252 exhibits a short post-antibiotic effect of 1·1 hours against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) following a 4-hour exposure period. The AFN-1252 unique spectrum of activity is not compromised by interactions with major antibiotic classes, but demonstrates synergy with low concentrations of gentamicin against MSSA and MRSA. These studies support the continued investigation of AFN-1252 as a targeted therapeutic for staphylococcal infections.

• Publication year

  2013

• Venue

  Journal of chemotherapy

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1179/1973947812Y.0000000063PMID 23433440PMCID 3558989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

  2012cited by this paper
• AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

  2009cited by this paper
• Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

  2008cited by this paper
• In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis

  2007cited by this paper
• Inhibiting Bacterial Fatty Acid Synthesis*

  2006cited by this paper
• Antibiotics in laboratory medicine

  2005cited by this paper
• Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.

  2005cited by this paper
• Structure and molecular organization of mammalian fatty acid synthase

  2005cited by this paper
• Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors*

  2005cited by this paper
• Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.

  2005cited by this paper
• Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

  2002cited by this paper
• Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics

  2002cited by this paper
• Antibiotics in laboratory medicine

  1987cited by this paper
• Effect of protein binding on antibiotic activity in vivo.

  1983cited by this paper

• Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus

  2024cites this paper
• Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance.

  2023cites this paper
• A Long Residence Time Enoyl-Reductase Inhibitor Explores an Extended Binding Region with Isoenzyme-Dependent Tautomer Adaptation and Differential Substrate-Binding Loop Closure.

  2021cites this paper
• N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae

  2021cites this paper
• Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms

  2020influential citation
• The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI)

  2020cites this paper
• Permissive Fatty Acid Incorporation in Host Environments Promotes Staphylococcal Adaptation to FASII Antibiotics

  2019cites this paper
• Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.

  2019cites this paper
• Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells.

  2019cites this paper
• Effect of commercial nasal steroid preparation on bacterial growth

  2019cites this paper
• A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.

  2018cites this paper
• A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production

  2018cites this paper
• Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus

  2017cites this paper
• Antimicrobial Activity and Resistance: Influencing Factors

  2017cites this paper
• Structural characterisation of the fatty acid biosynthesis enzyme FabF from the pathogen Listeria monocytogenes

  2017cites this paper
• Bacterial fatty acid metabolism in modern antibiotic discovery.

  2017cites this paper
• Development of biotin protein ligase inhibitors as new antibiotics to treat Staphylococcus aureus

  2017influential citation
• Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

  2016cites this paper
• Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes

  2016cites this paper
• Antibiotics in the clinical pipeline at the end of 2015

  2016cites this paper
• Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials

  2016cites this paper
• Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics.

  2016cites this paper
• Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria*

  2015cites this paper
• How Bacterial Pathogens Eat Host Lipids: Implications for the Development of Fatty Acid Synthesis Therapeutics*

  2015cites this paper
• Initial Broth Microdilution Quality Control Guidelines for Debio 1452, a FabI Inhibitor Antimicrobial Agent

  2015cites this paper
• Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains

  2015cites this paper
• Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.

  2015cites this paper
• Auxotrophs Do Not Proliferate in Mice Staphylococcus aureus Fatty Acid

  2014cites this paper
• Resistance to AFN-1252 Arises from Missense Mutations in Staphylococcus aureus Enoyl-acyl Carrier Protein Reductase (FabI)*

  2013cites this paper
• Staphylococcus aureus Fatty Acid Auxotrophs Do Not Proliferate in Mice

  2013cites this paper
• Recent Advances in Inhibitors of Bacterial Fatty Acid Synthesis Type II (FASII) System Enzymes as Potential Antibacterial Agents

  2013cites this paper
• 3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.

  2013cites this paper
• AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

  2013cites this paper